202 related articles for article (PubMed ID: 27320114)
21. A review of tumour lysis syndrome with targeted therapies and the role of rasburicase.
Bose P; Qubaiah O
J Clin Pharm Ther; 2011 Jun; 36(3):299-326. PubMed ID: 21501203
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.
Knoebel RW; Lo M; Crank CW
J Oncol Pharm Pract; 2011 Sep; 17(3):147-54. PubMed ID: 20332174
[TBL] [Abstract][Full Text] [Related]
23. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review.
Coiffier B; Altman A; Pui CH; Younes A; Cairo MS
J Clin Oncol; 2008 Jun; 26(16):2767-78. PubMed ID: 18509186
[TBL] [Abstract][Full Text] [Related]
24. SFCE (Société Française de Lutte contre les Cancers et Leucémies de l'Enfant et de l'Adolescent) recommendations for the management of tumor lysis syndrome (TLS) with rasburicase: an observational survey.
Bertrand Y; Mechinaud F; Brethon B; Mialou V; Auvrignon A; Nelken B; Notz-Carrère A; Plantaz D; Patte C; Urbieta M; Baruchel A; Leverger G;
J Pediatr Hematol Oncol; 2008 Apr; 30(4):267-71. PubMed ID: 18391694
[TBL] [Abstract][Full Text] [Related]
25. Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique.
Darmon M; Vincent F; Camous L; Canet E; Bonmati C; Braun T; Caillot D; Cornillon J; Dimicoli S; Etienne A; Galicier L; Garnier A; Girault S; Hunault-Berger M; Marolleau JP; Moreau P; Raffoux E; Recher C; Thiebaud A; Thieblemont C; Azoulay E;
Br J Haematol; 2013 Aug; 162(4):489-97. PubMed ID: 23772757
[TBL] [Abstract][Full Text] [Related]
26. Rasburicase for the treatment of tumor lysis in hematological malignancies.
Malaguarnera G; Giordano M; Malaguarnera M
Expert Rev Hematol; 2012 Feb; 5(1):27-38. PubMed ID: 22272702
[TBL] [Abstract][Full Text] [Related]
27. Risk-based management strategy and outcomes of tumor lysis syndrome in children with leukemia/lymphoma: Analysis from a resource-limited setting.
Gopakumar KG; Seetharam S; Km JK; Nair M; Rajeswari B; Cs G; Vr P; Thankamony P
Pediatr Blood Cancer; 2018 Dec; 65(12):e27401. PubMed ID: 30101454
[TBL] [Abstract][Full Text] [Related]
28. Preventing Tumor Lysis Syndrome: Two Case Studies of Unexpected Outcomes.
Sleutel MR; Brown W; Wells JN
Clin J Oncol Nurs; 2016 Apr; 20(2):195-200. PubMed ID: 26991714
[TBL] [Abstract][Full Text] [Related]
29. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults.
McDonnell AM; Lenz KL; Frei-Lahr DA; Hayslip J; Hall PD
Pharmacotherapy; 2006 Jun; 26(6):806-12. PubMed ID: 16716134
[TBL] [Abstract][Full Text] [Related]
30. Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.
Vines AN; Shanholtz CB; Thompson JL
Ann Pharmacother; 2010 Oct; 44(10):1529-37. PubMed ID: 20841516
[TBL] [Abstract][Full Text] [Related]
31. Treatment outcome of metastatic testicular cancer at a single institution in Japan, a country with low incidence of germ cell tumor.
Kawai K; Hinotsu S; Oikawa T; Sekido N; Hattori K; Miyanaga N; Hasegawa Y; Kojima H; Shimazui T; Akaza H
Jpn J Clin Oncol; 2006 Nov; 36(11):723-30. PubMed ID: 17082218
[TBL] [Abstract][Full Text] [Related]
32. Tumour lysis syndrome.
Calvo Villas JM
Med Clin (Barc); 2019 May; 152(10):397-404. PubMed ID: 30612747
[TBL] [Abstract][Full Text] [Related]
33. Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours.
Gizzi M; Oberic L; Massard C; Poterie A; Le Teuff G; Loriot Y; Albiges L; Baciarello G; Michels J; Bossi A; Blanchard P; Escudier B; Fizazi K
Eur J Cancer; 2016 Dec; 69():151-157. PubMed ID: 27821318
[TBL] [Abstract][Full Text] [Related]
34. Tumor lysis syndrome: risk factors, diagnosis, and management.
Burns RA; Topoz I; Reynolds SL
Pediatr Emerg Care; 2014 Aug; 30(8):571-6; quiz 577-9. PubMed ID: 25098804
[TBL] [Abstract][Full Text] [Related]
35. Rasburicase in the prevention and treatment of tumour lysis syndrome.
Mayne N; Keady S; Thacker M
Intensive Crit Care Nurs; 2008 Feb; 24(1):59-62. PubMed ID: 17698360
[TBL] [Abstract][Full Text] [Related]
36. Advanced germ cell tumors and chemotherapy in G6PD deficient patients: Yes to chemotherapy but no to rasburicase and some premedications.
Gazouli I; Baltogiannis D; Ntellas P; Smaragdi Vlachou M; Tagkas C; Champilomatis I; Kampletsas Ε; Tolia M; Mauri D
J BUON; 2021; 26(4):1642-1646. PubMed ID: 34565030
[TBL] [Abstract][Full Text] [Related]
37. Tumour lysis syndrome: a rare side effect of imatinib therapy for GIST.
Ondecker J; Kordic G; Jordan K
BMJ Case Rep; 2018 Nov; 11(1):. PubMed ID: 30567109
[TBL] [Abstract][Full Text] [Related]
38. Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients.
Annemans L; Moeremans K; Lamotte M; Garcia Conde J; van den Berg H; Myint H; Pieters R; Uyttebroeck A
Support Care Cancer; 2003 Apr; 11(4):249-57. PubMed ID: 12673464
[TBL] [Abstract][Full Text] [Related]
39. A Clinical and Economic Comparison of Rasburicase and Allopurinol in the Treatment of Patients With Clinical or Laboratory Tumor Lysis Syndrome.
Cairo MS; Thompson S; Tangirala K; Eaddy MT
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):173-178. PubMed ID: 27965022
[TBL] [Abstract][Full Text] [Related]
40. [High dose chemotherapy with autologous stem-cell support in germ cell tumors: The Instituto Português de Oncologia de Lisboa Francisco Gentil Series].
Brito M; Sanchez P; Velho S; Miranda N; Leal da Costa F; Ferreira I; Teixeira G; Guimarães A; Abecasis M; Passos Coelho JL
Acta Med Port; 2011; 24(4):533-44. PubMed ID: 22521011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
